Francesca De Nicola

Francesca De Nicola

Auto-generated profile, based on publicly available information

Francesca De Nicola

SAFU Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
LBLaura Belloni
Laura Belloni
TPTeresa Pollicino
Teresa Pollicino
FNFrancesca De Nicola
Francesca De Nicola
FGFrancesca Guerrieri
Francesca Guerrieri
GRGiuseppina Raffa
Giuseppina Raffa
MLMassimo Levrero
Massimo Levrero
HBV cccDNA, the template for transcription of all viral mRNAs, accumulates in the nucleus of infected cells as a stable episome organized into minichromosomes by histones and non-histone viral and cellular proteins. Using a cccDNA-specific chromatin immunoprecipitation (ChIP)-based quantitative assay, we have previously shown that transcription of the HBV minichromosome is regulated by epigenetic changes of cccDNA-bound histones and that modulation of the acetylation status of cccDNA-bound H3/H4 histones impacts on HBV replication. We now show that the cellular histone acetyltransferases CBP, p300, and PCAF/GCN5, and the histone deacetylases HDAC1 and hSirt1 are all recruited in vivo onto the cccDNA. We also found that the HBx regulatory protein produced in HBV replicating cells is recruited onto the cccDNA minichromosome, and the kinetics of HBx recruitment on the cccDNA parallels the HBV replication. As expected, an HBV mutant that does not express HBx is impaired in its replication, and exogenously expressed HBx transcomplements the replication defects. p300 recruitment is severely impaired, and cccDNA-bound histones are rapidly hypoacetylated in cells replicating the HBx mutant, whereas the recruitment of the histone deacetylases hSirt1 and HDAC1 is increased and occurs at earlier times. Finally, HBx mutant cccDNA transcribes significantly less pgRNA. Altogether our results further support the existence of a complex network of epigenetic events that influence cccDNA function and HBV replication and identify an epigenetic mechanism (i.e., to prevent cccDNA deacetylation) by which HBx controls HBV replication.

16 August 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
EBElisabetta Botti
Elisabetta Botti
GSGiulia Spallone
Giulia Spallone
FMFrancesca Moretti
Francesca Moretti
BMBarbara Marinari
Barbara Marinari
VPValentina Pinetti
Valentina Pinetti
ACAntonio Costanzo
Antonio Costanzo
The transcription factor interferon regulatory factor 6 (IRF6) regulates craniofacial development and epidermal proliferation. We recently showed that IRF6 is a component of a regulatory feedback loop that controls the proliferative potential of epidermal cells. IRF6 is transcriptionally activated by p63 and induces its proteasome-mediated down-regulation, thereby limiting keratinocyte proliferative potential. We hypothesized that IRF6 may also be involved in skin carcinogenesis. Hence, we analyzed IRF6 expression in a large series of squamous cell carcinomas (SCCs) and found a strong down-regulation of IRF6 that correlated with tumor invasive and differentiation status. IRF6 down-regulation in SCC cell lines and primary tumors correlates with methylation on a CpG dinucleotide island located in its promoter region. To identify the molecular mechanisms regulating IRF6 potential tumor suppressive activity, we performed a genome-wide analysis by combining ChIP sequencing for IRF6 binding sites and gene expression profiling in primary human keratinocytes after siRNA-mediated IRF6 depletion. We observed dysregulation of cell cycle-related genes and genes involved in differentiation, cell adhesion, and cell–cell contact. Many of these genes were direct IRF6 targets. We also performed in vitro invasion assays showing that IRF6 down-regulation promotes invasive behavior and that reintroduction of IRF6 into SCC cells strongly inhibits cell growth. These results indicate a function for IRF6 in suppression of tumorigenesis in stratified epithelia.

1 December 2006 in Cancer Cell
Verified
Journal Article
Closed access
TBTiziana Bruno
Tiziana Bruno
FNFrancesca De Nicola
Francesca De Nicola
SISimona Iezzi
Simona Iezzi
DLDaniele Lecis
Daniele Lecis
CDCarmen D'Angelo
Carmen D'Angelo
MFMaurizio Fanciulli
Maurizio Fanciulli

6 April 2017 in Gut
Verified
Journal Article
Open access
PDF file
GMGwenola Manic
Gwenola Manic
MSMichele Signore
Michele Signore
ASAntonella Sistigu
Antonella Sistigu
GRGiorgio Russo
Giorgio Russo
FCFrancesca Corradi
Francesca Corradi
RMRuggero De Maria
Ruggero De Maria
Objective: Cancer stem cells (CSCs) are responsible for tumour formation and spreading, and their targeting is required for tumour eradication. There are limited therapeutic options for advanced colorectal cancer (CRC), particularly for tumours carrying RAS-activating mutations. The aim of this study was to identify novel CSC-targeting strategies.Design: To discover potential therapeutics to be clinically investigated as single agent, we performed a screening with a panel of FDA-approved or investigational drugs on primary CRC cells enriched for CSCs (CRC-SCs) isolated from 27 patients. Candidate predictive biomarkers of efficacy were identified by integrating genomic, reverse-phase protein microarray (RPPA) and cytogenetic analyses, and validated by immunostainings. DNA replication stress (RS) was increased by employing DNA replication-perturbing or polyploidising agents.Results: The drug-library screening led to the identification of LY2606368 as a potent anti-CSC agent acting in vitro and in vivo in tumour cells from a considerable number of patients (∼36%). By inhibiting checkpoint kinase (CHK)1, LY2606368 affected DNA replication in most CRC-SCs, including RAS-mutated ones, forcing them into premature, lethal mitoses. Parallel genomic, RPPA and cytogenetic analyses indicated that CRC-SCs sensitive to LY2606368 displayed signs of ongoing RS response, including the phosphorylation of RPA32 and ataxia telangiectasia mutated serine/threonine kinase (ATM). This was associated with mutation(s) in TP53 and hyperdiploidy, and made these CRC-SCs exquisitely dependent on CHK1 function. Accordingly, experimental increase of RS sensitised resistant CRC-SCs to LY2606368.Conclusions: LY2606368 selectively eliminates replication-stressed, p53-deficient and hyperdiploid CRC-SCs independently of RAS mutational status. These results provide a strong rationale for biomarker-driven clinical trials with LY2606368 in patients with CRC.

1 November 2019 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
FGFrauke Goeman
Frauke Goeman
FNFrancesca De Nicola
Francesca De Nicola
SSStefano Scalera
Stefano Scalera
FSFrancesca Sperati
Francesca Sperati
EGEnzo Gallo
Enzo Gallo
MMMarcello Maugeri-Saccà
Marcello Maugeri-Saccà

1 November 2002 in Cancer Cell
Verified
Journal Article
Closed access
TBTiziana Bruno
Tiziana Bruno
RARoberta De Angelis
Roberta De Angelis
FNFrancesca De Nicola
Francesca De Nicola
CBChristian Barbato
Christian Barbato
MPMonica Di Padova
Monica Di Padova
MFMaurizio Fanciulli
Maurizio Fanciulli